Cargando…

Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology

The practice of liquid biopsy (LB) has revolutionized the care of patients with metastatic lung cancer. Many oncologists now use this approach in daily practice, applying precise procedures for the detection of activating or resistance mutations in EGFR. These tests are performed with plasma DNA and...

Descripción completa

Detalles Bibliográficos
Autor principal: Hofman, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704172/
https://www.ncbi.nlm.nih.gov/pubmed/29125548
http://dx.doi.org/10.3390/cancers9110154
_version_ 1783281832366702592
author Hofman, Paul
author_facet Hofman, Paul
author_sort Hofman, Paul
collection PubMed
description The practice of liquid biopsy (LB) has revolutionized the care of patients with metastatic lung cancer. Many oncologists now use this approach in daily practice, applying precise procedures for the detection of activating or resistance mutations in EGFR. These tests are performed with plasma DNA and have been approved as companion diagnostic test for patients treated with tyrosine kinase inhibitors. ALK is another important target in lung cancer since it leads to treatment of patients who are positive for a rearrangement in ALK identified with tumor tissue. By analogy with EGFR, LB for detection of genomic alterations in ALK (rearrangements or mutations) has been rapidly adopted in the clinic. However, this promising approach has some limitations and has not yet been disseminated as much as the blood test targeting EGFR. In addition to these two therapeutic targets LB can be used for evaluation of the genomic status of other genes of interest of patients with lung cancer (ROS1, RET, NTRK MET, BRAF, HER2, etc.). LB can be performed to evaluate a specific target or for a more or less complex panel of genes. Considering the number of potential targets for clinical trials, techniques of next-generation sequencing of circulating DNA are on the rise. This review will provide an update on the contribution of LB to care of patients with metastatic lung cancer, including the present limits of this approach, and will consider certain perspectives.
format Online
Article
Text
id pubmed-5704172
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57041722017-11-30 Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology Hofman, Paul Cancers (Basel) Review The practice of liquid biopsy (LB) has revolutionized the care of patients with metastatic lung cancer. Many oncologists now use this approach in daily practice, applying precise procedures for the detection of activating or resistance mutations in EGFR. These tests are performed with plasma DNA and have been approved as companion diagnostic test for patients treated with tyrosine kinase inhibitors. ALK is another important target in lung cancer since it leads to treatment of patients who are positive for a rearrangement in ALK identified with tumor tissue. By analogy with EGFR, LB for detection of genomic alterations in ALK (rearrangements or mutations) has been rapidly adopted in the clinic. However, this promising approach has some limitations and has not yet been disseminated as much as the blood test targeting EGFR. In addition to these two therapeutic targets LB can be used for evaluation of the genomic status of other genes of interest of patients with lung cancer (ROS1, RET, NTRK MET, BRAF, HER2, etc.). LB can be performed to evaluate a specific target or for a more or less complex panel of genes. Considering the number of potential targets for clinical trials, techniques of next-generation sequencing of circulating DNA are on the rise. This review will provide an update on the contribution of LB to care of patients with metastatic lung cancer, including the present limits of this approach, and will consider certain perspectives. MDPI 2017-11-10 /pmc/articles/PMC5704172/ /pubmed/29125548 http://dx.doi.org/10.3390/cancers9110154 Text en © 2017 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hofman, Paul
Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
title Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
title_full Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
title_fullStr Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
title_full_unstemmed Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
title_short Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
title_sort liquid biopsy and therapeutic targets: present and future issues in thoracic oncology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704172/
https://www.ncbi.nlm.nih.gov/pubmed/29125548
http://dx.doi.org/10.3390/cancers9110154
work_keys_str_mv AT hofmanpaul liquidbiopsyandtherapeutictargetspresentandfutureissuesinthoraciconcology